Genetics News

Stay updated on genetics with press releases highlighting research, innovations, and applications driving advancements in genetic science. Learn about key developments shaping genetics and explore opportunities in genomics, gene editing, and personalized healthcare.

Nov 17, 2026 at 7:00 PM

Shionogi Completes Acquisition of IntraBio Inc. and Adds AQNEURSA® (levacetylleucine) to Growing Rare Disease Global Portfolio

OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that it has completed the acquisition of IntraBio Inc. (“IntraBio”). The acquisition adds AQNEURSA® (levacetylleucine) and additional rare disease capabilities to Shionogi's growing global portfolio. AQNEURSA was approved by the U.S. Food and Drug Administration in 2024 and by the European Medicines Agency (EMA) in January 2026 for n...
Nov 17, 2026 at 5:34 PM

City of Hope Researchers Present Outpatient CAR T Advances, Novel Cell Therapies and Targeted Regimens at ASH 2026

LOS ANGELES--(BUSINESS WIRE)--City of Hope will present new research on cellular therapies and targeted treatments for blood cancers at the 2026 ASH Annual Meeting and Exposition....
Nov 17, 2026 at 5:00 PM

Octant Appoints Eddy Anglade, M.D., as Chief Medical Officer

EMERYVILLE, Calif.--(BUSINESS WIRE)--Octant, Inc., a clinical-stage drug discovery company developing corrector therapies for protein misfolding diseases, today announced the appointment of Eddy Anglade, M.D., as its first Chief Medical Officer. Dr. Anglade will lead Octant’s clinical development strategy, including advancing its lead program, OCT-980 for rhodopsin-associated autosomal dominant retinitis pigmentosa (RHO-adRP). “OCT-980 is the first molecule from our platform to reach patients,...
Nov 17, 2026 at 4:30 PM

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on October 22, 2026, the Compensation Committee of the Company’s Board of Directors approved “inducement” grants to 203 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 196,885 restricted stock units. The grants are outside the Company’s stockholder-approv...
Nov 17, 2026 at 4:01 PM

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on November 16, 2026, it granted stock options to purchase an aggregate of 99,050 shares of common stock to ele...
Nov 17, 2026 at 12:04 PM

TreeFrog Therapeutics Appoints James Sterling as Chief Financial Officer

BORDEAUX, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)--TreeFrog Therapeutics, a biotechnology company developing scalable cell therapies built on its proprietary C-Stem™ technology, today announced the appointment of James Sterling as Chief Financial Officer, effective November 1, 2026. James joins TreeFrog’s executive leadership team and reports to Mark Rothera, President and Chief Executive Officer. He oversees finance, investor relations and corporate development as the company enters its nex...
Nov 17, 2026 at 11:45 AM

HLTH 2026 Names Natera Best-in-Class Winner in Cancer, Screening & Early Detection

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it has been named the Best in Class winner in the Cancer, Screening & Early Detection category at the Digital Health Hub Foundation Digital Health & AI Awards. The recognition highlights the impact of Natera’s Signatera™ molecular residual disease (MRD) test on cancer care.The winners were announced live at the 2026 HLTH Conference in Las Vegas. This...
Nov 17, 2026 at 9:17 AM

Cardio Diagnostics to Unveil Non-Obstructive Coronary Artery Disease Data, FDA Breakthrough Device Designation Strategy, and India Launch Update on December 10 Investor Call

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. will host an investor conference call on Thursday, December 10, 2026, at 11 a.m. Central Time....
Nov 17, 2026 at 8:32 AM

Samaritan Health Selects MEDITECH Expanse to Establish ‘One Patient, One Record’

CANTON, Mass.--(BUSINESS WIRE)--Samaritan Health will implement MEDITECH Expanse across its hospital, clinics, specialty practices, and Home Health services....
Nov 17, 2026 at 8:00 AM

Alloy Therapeutics Introduces TEMPER™, a Proprietary siRNA Platform Designed to Advance Targeted Extrahepatic Delivery

BOSTON--(BUSINESS WIRE)--Alloy Therapeutics, a biotechnology ecosystem company dedicated to democratizing access to drug discovery technologies and capabilities, today announced the introduction of TEMPER™ (Targeted Extra-Hepatic Modular Precision-Engineered RNA), a proprietary siRNA platform designed to advance targeted delivery of RNA therapeutics beyond the liver. The platform incorporates delivery technology accessed through a strategic transaction with Transcera, expanding Alloy's capabilit...
Turn Your News Into Headlines
Submit Your Release

Get Story Ideas Delivered to Your Inbox

Sign Up